ArticleCurrent topics in medicinal chemistry2025
Bioactive Compound Chemistry and Antiasthmatic Activity of Betulinic Acid and Taraxerol in Experimental Models.
Article in Current topics in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Taraxerol Alleviates Cerebral Ischemia-Reperfusion Induced Inflammation and Ferroptosis via Regulating AKT/NF-κB Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe natural molecules betulinic acid (BA) and taraxerol (T) have many biological and therapeutic uses, one of which is the relief from asthma symptoms. This study wasThis study aimed to assess BA and T effectiveness in treating bronchial asthma and perform a molecular docking study to find the binding energy of BA and T with β-adrenoceptor.
methodsUsing ethanol as the solvent, the Bacopa monnieri leaves were extracted using a soxhlet equipment. As a reference medicine, budesenoid was utilised. With PyRx 0.8, the molecular docking experiment was conducted using AutoDock vina. The protocol followed by the acute toxicity study was the OECD guideline 425. The effectiveness of the test medication in alleviating asthma was determined using an anaphylactic microshock model in guinea pigs.
resultsMolecular docking analysis showed high binding affinities of BA (-7.95 kcal/mol) and T (-8.23 kcal/mol) to LOX-5, which could suppress the synthesis of leukotriene, one of the central mediators of asthma pathogenesis. In vivo study, the BA and T treatment prolonged pre-convulsion time in guinea pigs up to 506.66 seconds as compared with the control (406.6 seconds, p < 0.05). This suggests protection against bronchial hyperresponsiveness. ELISA assays demonstrated that BA and T decreased the levels of TNF-α and increased IL-10, indicating a potential modulation of inflammation (p < 0.05). Markers of oxidative stress were lowered in treated animals, as demonstrated by the lowered MDA and enhanced activities of antioxidant enzymes such as SOD, CAT, and GSH, suggesting a protective effect against oxidative lung damage (p < 0.05). Histological analysis confirmed a decrease in inflammatory cell infiltration and airway remodeling in the treated groups compared to the OVA-induced controls.
conclusionThe results of the animal studies showed that BA and T reduced anaphylaxis, suggesting that it could be a viable alternative to current asthma treatments in the future. The results of the molecular docking investigation, however, showed that BA and T may indeed bind to the target receptor, opening the door to new treatment possibilities.
Indexed as
Identifiers
40325532What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.